Wuhan, China

Shaohua Chang

This inventor holds 1 USPTO granted patent and 5 published patent applications, plus 1 CIPO patent. Top assignee: Wuhan Humanwell Innovative Drug Research and Development Center Limited Company. Active years: 2026.

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Shaohua Chang - Innovator in Cancer and Inflammation Research

Introduction

Shaohua Chang is a prominent inventor based in Wuhan, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target specific biological pathways. His work focuses on creating innovative solutions for cancer and inflammation treatment.

Latest Patents

Shaohua Chang holds 1 patent for his invention titled "Synthesis of novel EP4 antagonist and use in cancer and inflammation." This patent describes a novel compound effective in antagonizing EP4, which is represented by a specific chemical formula. The compound may also exist in various forms, including tautomers, stereoisomers, hydrates, solvates, pharmaceutically acceptable salts, or prodrugs.

Career Highlights

Chang is associated with the Wuhan Humanwell Innovative Drug Research and Development Center Limited Company, where he applies his expertise in drug development. His work is instrumental in advancing therapeutic options for patients suffering from cancer and inflammatory diseases.

Collaborations

He collaborates with Yang Zang, contributing to the innovative research environment at their institution.

Conclusion

Shaohua Chang's contributions to pharmaceutical innovation highlight his commitment to improving healthcare through targeted therapies. His work continues to pave the way for advancements in cancer and inflammation treatment.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…